Cargando…

Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study

INTRODUCTION: Precapillary pulmonary hypertension (PH) implies a worse prognosis in myeloproliferative neoplasms (MPN). N-terminal pro-B-type natriuretic peptide (NT-proBNP) is elevated in cardiopulmonary involvement. In MPN patients with precapillary PH, elevated vascular endothelial growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Költő, Gyöngyvér, Tőkés-Füzesi, Margit, Papp, Előd, Adravetz, Zsófia, Komócsi, András, Egyed, Miklós, Faludi, Réka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641504/
https://www.ncbi.nlm.nih.gov/pubmed/34900042
http://dx.doi.org/10.5114/aoms.2020.93315
_version_ 1784609508294656000
author Költő, Gyöngyvér
Tőkés-Füzesi, Margit
Papp, Előd
Adravetz, Zsófia
Komócsi, András
Egyed, Miklós
Faludi, Réka
author_facet Költő, Gyöngyvér
Tőkés-Füzesi, Margit
Papp, Előd
Adravetz, Zsófia
Komócsi, András
Egyed, Miklós
Faludi, Réka
author_sort Költő, Gyöngyvér
collection PubMed
description INTRODUCTION: Precapillary pulmonary hypertension (PH) implies a worse prognosis in myeloproliferative neoplasms (MPN). N-terminal pro-B-type natriuretic peptide (NT-proBNP) is elevated in cardiopulmonary involvement. In MPN patients with precapillary PH, elevated vascular endothelial growth factor (VEGF) values, but in left heart (LH) disease patients, decreased values were reported. Our aim was to determine whether a combination of NT-proBNP and VEGF is suitable for the detection of the precapillary forms of PH in MPN patients. MATERIAL AND METHODS: Eighty-one MPN patients were investigated. Pulmonary hypertension was defined as Doppler-derived systolic pulmonary artery pressure (sPAP) ≥ 40 mm Hg. Patient groups with cardiopulmonary involvement (precapillary PH, PH due to LH disease, left ventricular ejection fraction < 50%, atrial fibrillation) or LH disease (PH due to LH disease, left ventricular ejection fraction < 50%, atrial fibrillation) were identified. RESULTS: In 9 patients PH was associated with LH disease. In 2 patients precapillary PH was found with extremely high NT-proBNP values. NT-proBNP significantly correlated with sPAP (r = 0.550; p < 0.001). NT-proBNP ≥ 466 pg/ml was the best predictor of cardiopulmonary involvement (AUC: 0.962, sensitivity: 86.7%, specificity: 93.9%). No correlation was found between VEGF levels and sPAP values. VEGF ≤ 431 pg/ml was the best predictor of LH disease (AUC: 0.609, sensitivity: 76.9%, specificity: 62.7%). CONCLUSIONS: NT-proBNP levels reflect cardiopulmonary involvement with high accuracy, but the combination of NT-proBNP and VEGF is not suitable for the detection of precapillary PH as the diagnostic power of VEGF is limited. Highly elevated NT-proBNP levels may suggest precapillary PH but further investigation is necessary for the exclusion of LH disease or atrial fibrillation.
format Online
Article
Text
id pubmed-8641504
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-86415042021-12-09 Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study Költő, Gyöngyvér Tőkés-Füzesi, Margit Papp, Előd Adravetz, Zsófia Komócsi, András Egyed, Miklós Faludi, Réka Arch Med Sci Clinical Research INTRODUCTION: Precapillary pulmonary hypertension (PH) implies a worse prognosis in myeloproliferative neoplasms (MPN). N-terminal pro-B-type natriuretic peptide (NT-proBNP) is elevated in cardiopulmonary involvement. In MPN patients with precapillary PH, elevated vascular endothelial growth factor (VEGF) values, but in left heart (LH) disease patients, decreased values were reported. Our aim was to determine whether a combination of NT-proBNP and VEGF is suitable for the detection of the precapillary forms of PH in MPN patients. MATERIAL AND METHODS: Eighty-one MPN patients were investigated. Pulmonary hypertension was defined as Doppler-derived systolic pulmonary artery pressure (sPAP) ≥ 40 mm Hg. Patient groups with cardiopulmonary involvement (precapillary PH, PH due to LH disease, left ventricular ejection fraction < 50%, atrial fibrillation) or LH disease (PH due to LH disease, left ventricular ejection fraction < 50%, atrial fibrillation) were identified. RESULTS: In 9 patients PH was associated with LH disease. In 2 patients precapillary PH was found with extremely high NT-proBNP values. NT-proBNP significantly correlated with sPAP (r = 0.550; p < 0.001). NT-proBNP ≥ 466 pg/ml was the best predictor of cardiopulmonary involvement (AUC: 0.962, sensitivity: 86.7%, specificity: 93.9%). No correlation was found between VEGF levels and sPAP values. VEGF ≤ 431 pg/ml was the best predictor of LH disease (AUC: 0.609, sensitivity: 76.9%, specificity: 62.7%). CONCLUSIONS: NT-proBNP levels reflect cardiopulmonary involvement with high accuracy, but the combination of NT-proBNP and VEGF is not suitable for the detection of precapillary PH as the diagnostic power of VEGF is limited. Highly elevated NT-proBNP levels may suggest precapillary PH but further investigation is necessary for the exclusion of LH disease or atrial fibrillation. Termedia Publishing House 2020-02-27 /pmc/articles/PMC8641504/ /pubmed/34900042 http://dx.doi.org/10.5114/aoms.2020.93315 Text en Copyright: © 2020 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Clinical Research
Költő, Gyöngyvér
Tőkés-Füzesi, Margit
Papp, Előd
Adravetz, Zsófia
Komócsi, András
Egyed, Miklós
Faludi, Réka
Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study
title Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study
title_full Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study
title_fullStr Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study
title_full_unstemmed Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study
title_short Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study
title_sort screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of n-terminal pro-b-type natriuretic peptide and vascular endothelial growth factor – a pilot study
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641504/
https://www.ncbi.nlm.nih.gov/pubmed/34900042
http://dx.doi.org/10.5114/aoms.2020.93315
work_keys_str_mv AT koltogyongyver screeningforprecapillarypulmonaryhypertensioninchronicmyeloproliferativedisorderstheroleofnterminalprobtypenatriureticpeptideandvascularendothelialgrowthfactorapilotstudy
AT tokesfuzesimargit screeningforprecapillarypulmonaryhypertensioninchronicmyeloproliferativedisorderstheroleofnterminalprobtypenatriureticpeptideandvascularendothelialgrowthfactorapilotstudy
AT pappelod screeningforprecapillarypulmonaryhypertensioninchronicmyeloproliferativedisorderstheroleofnterminalprobtypenatriureticpeptideandvascularendothelialgrowthfactorapilotstudy
AT adravetzzsofia screeningforprecapillarypulmonaryhypertensioninchronicmyeloproliferativedisorderstheroleofnterminalprobtypenatriureticpeptideandvascularendothelialgrowthfactorapilotstudy
AT komocsiandras screeningforprecapillarypulmonaryhypertensioninchronicmyeloproliferativedisorderstheroleofnterminalprobtypenatriureticpeptideandvascularendothelialgrowthfactorapilotstudy
AT egyedmiklos screeningforprecapillarypulmonaryhypertensioninchronicmyeloproliferativedisorderstheroleofnterminalprobtypenatriureticpeptideandvascularendothelialgrowthfactorapilotstudy
AT faludireka screeningforprecapillarypulmonaryhypertensioninchronicmyeloproliferativedisorderstheroleofnterminalprobtypenatriureticpeptideandvascularendothelialgrowthfactorapilotstudy